

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KINGWORLD MEDICINES GROUP LIMITED
金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

POSITIVE PROFIT ALERT

This announcement is made by Kingworld Medicines Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 (the “**Period**”) and the information currently available to the Board, the Group is expected to record an increase in the profit of the Group by approximately 35% to 40% for the Period as compared to the profit of the Group of RMB35.1 million for the six months ended 30 June 2022 (the “**Previous Period**”).

The Board considers that the increase in the profit of the Group was mainly due to (i) an increase in revenue and gross profit from distribution of imported branded pharmaceutical and healthcare products in China by approximately 30% to 35% and 15% to 20%, respectively; and (ii) an increase in the share of profit of a joint venture by approximately 55% to 60% for the Period as compared to the Previous Period as a result of the market recovery from the lifting of the COVID-19 pandemic control measures.

Information contained in this announcement is based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the Period and information currently available to the Board. Information in this announcement has not been reviewed nor audited by the auditors of the Company, or reviewed by the audit committee of the Company. The actual results of the Group for the Period are subject to adjustment and may differ from the information disclosed herein. Shareholders and potential investors are advised to read carefully the results announcement of the Group for the Period, which is expected to be published by the Company on 28 August 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares in the Company.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 2 August 2023

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San, and Mr. Zhou Xuhua, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.